StockData
Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc. (RLMD) income statement

RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$2.62−0.49 (-15.76%)

Close on Nov 20, 2026Market cap $279.48MP/E –Yield –

See a number that looks wrong?